Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

Phase 1

Completed

Conditions: Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

Interventions: Biological: PF-04950615 (RN316)

First Posted Date: 2011-09-16

Last Posted Date: 2018-07-23

Lead Sponsor: Pfizer

Target Recruit Count: 49

Registration Number: NCT01435382

Locations: 🇺🇸
Jasper Clinic, Inc., Kalamazoo, Michigan, United States
🇺🇸
Prism Research, Saint Paul, Minnesota, United States
🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States

and more 4 locations

The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin

Phase 3

Completed

Conditions: Transthyretin Familial Amyloid Polyneuropathy

Interventions: Drug: tafamidis

First Posted Date: 2011-09-16

Last Posted Date: 2015-09-09

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT01435655

Locations: 🇯🇵
Kumamoto University Hospital/Department of Neurology, Kumamoto-shi, Kumamoto, Japan
🇯🇵
Shinshu University Hospital/Department of Medicine (Neurology and Reumatology), Matsumoto-shi, Nagano, Japan

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: desvenlafaxine succinate sustained-release 50 mg/day
Drug: desvenlafaxine succinate sustained-release 100 mg/day
Drug: placebo

First Posted Date: 2011-09-13

Last Posted Date: 2014-01-20

Lead Sponsor: Pfizer

Target Recruit Count: 924

Registration Number: NCT01432457

Locations: 🇺🇸
Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States
🇺🇸
Clinical Innovations, Inc., San Diego, California, United States
🇺🇸
Patient Priority Clinical Sites, LLC, Cincinnati, Ohio, United States

and more 54 locations

Correlation Between Beliefs About Medicine and Objective Measures of Efficacy and Safety in Rheumatoid Arthritis (RA)

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: SC anti-TNF

First Posted Date: 2011-09-13

Last Posted Date: 2016-01-20

Lead Sponsor: Pfizer

Target Recruit Count: 460

Registration Number: NCT01432366

Locations: 🇧🇪
Algemeen Ziekenhuis St Jan, Brugge, Belgium

A Study To Evaluate PF-05175157 In Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: PF-05175157
Drug: Placebo

First Posted Date: 2011-09-13

Last Posted Date: 2012-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT01433380

Locations: 🇺🇸
Pfizer Investigational Site, Baton Rouge, Louisiana, United States

13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: vaccine-13vPnC

First Posted Date: 2011-09-12

Last Posted Date: 2013-01-25

Lead Sponsor: Pfizer

Target Recruit Count: 324

Registration Number: NCT01432262

Locations: 🇲🇽
Star Medica, Morelia, Michoacan, Mexico
🇲🇽
Hospital General de Durango, Durango, Mexico
🇲🇽
Instituto Mexicano de Investigación Clínica, S.A. de C.V, Mexico, D.f., Mexico

and more 1 locations

Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis

Withdrawn

Conditions: Pediatric Psoriasis

Interventions: Drug: Enbrel group

First Posted Date: 2011-09-12

Last Posted Date: 2013-11-18

Lead Sponsor: Pfizer

Registration Number: NCT01432249

A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CAZ104
Drug: Avibactam
Drug: Ceftazidime

First Posted Date: 2011-09-09

Last Posted Date: 2017-09-01

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT01430910

Locations: 🇬🇧
Research site, London, United Kingdom

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Phase 2

Completed

Conditions: Migraine
Acute Treatment of Migraine

Interventions: Drug: Rimegepant
Drug: Placebo
Drug: Sumatriptan

First Posted Date: 2011-09-08

Last Posted Date: 2023-02-28

Lead Sponsor: Pfizer

Target Recruit Count: 1026

Registration Number: NCT01430442

Locations: 🇺🇸
Broward Research Group, Pembroke Pines, Florida, United States
🇺🇸
Clinical Res. Advantage Inc/ Desert Clinical Research Llc, Tempe, Arizona, United States
🇺🇸
Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States

and more 37 locations

Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

Phase 2

Terminated

Conditions: Early Breast Cancer (Phase 2)
Advanced Breast Cancer (Phase 1b)

Interventions: Drug: PF-04691502 in combination with Letrozole
Drug: PF-04691502
Drug: Letrozole

First Posted Date: 2011-09-08

Last Posted Date: 2014-08-12

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT01430585

Locations: 🇸🇪
Pfizer Investigational Site, Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy